| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75c0800b8975f37c915736e35c53c95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57937a7dfc9334967c93474d21f85e0a |
| publicationDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019046859-A1 |
| titleOfInvention |
ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
| abstract |
The present invention relates to antibody-drug conjugates (ADCs) comprising a cytotoxic or cytostatic agent linked to an anti-EGFR antibody via a linker, compositions comprising ADCs, methods of preparing ADCs, and methods for treating cancer by administering ADCs to a subject suffering from cancer. The present invention relates to ADCs which bind specifically to EGFR, and in particular to human EGFR (hEGFR). The anti-EGFR antibody according to the invention comprises a S239C mutation in a heavy chain constant region, the numbering being in accordance with the Kabat numbering. In some embodiments, the heavy chain constant region of the anti-EGFR antibody is either free of C-terminal lysine or comprises an amino acid other than lysine at a C-terminal end of the constant region of the heavy chain. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022098242-A1 |
| priorityDate |
2017-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |